Table of Contents Table of Contents
Previous Page  547 / 1851 Next Page
Information
Show Menu
Previous Page 547 / 1851 Next Page
Page Background

Checkpoint blocade

Ribas NEJM 2012

CTLA-4 inhibition

Ipilimumab/Tremelimumab

PD-L1 inhibition

Pembrolizumab/Nivolumab/

Duravulumab/Avelumab

48h